Drug:
Reaction: PRODUCT USE ISSUE
20260101 - 20261231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 26940065 |
EU |
2 | |
Death, Product use issue, |
||||
TECLISTAMAB-CQYV, DARATUMUMAB, |
||||
| 2 | 26940185 |
US |
66 | 1 |
Syncope, Product availability issue, Malaise, Product use issue, |
||||
LACOSAMIDE, |
||||
| 3 | 26940252 |
US |
45 | 1 |
Product use issue, |
||||
DUPILUMAB, |
||||
| 4 | 26940342 |
US |
||
Product use issue, |
||||
| 5 | 26940392 |
CA |
18 | 1 |
Gastric ulcer, Crohn^s disease, Product use issue, |
||||
INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, |
||||
| 6 | 26940491 |
KR |
8 | 1 |
Pyrexia, Acute sinusitis, Oropharyngeal pain, Product use issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 7 | 26940572 |
CN |
51 | 1 |
Diabetes insipidus, Hypovolaemic shock, Product use issue, |
||||
DEXMEDETOMIDINE, PROPOFOL, SEVOFLURANE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, PALONOSETRON HYDROCHLORIDE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, |
||||
| 8 | 26940739 |
US |
2 | |
Sciatica, Incorrect dose administered, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 9 | 26940900 |
|||
Tendon disorder, Product use issue, |
||||
ALENDRONATE SODIUM, ALENDRONATE SODIUM TABLET, |
||||
| 10 | 26940961 |
US |
2 | |
Injection site urticaria, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 11 | 26941054 |
US |
2 | |
Abdominal pain, Product use issue, |
||||
| 12 | 26941060 |
US |
2 | |
Drug intolerance, Gait disturbance, Dyspnoea, Pain in extremity, Arthralgia, Fatigue, Bone pain, Headache, Product use issue, Off label use, |
||||
ABALOPARATIDE, ABALOPARATIDE, ABALOPARATIDE, ABALOPARATIDE, ABALOPARATIDE, |
||||
| 13 | 26941194 |
MX |
61 | |
General physical condition abnormal, Early satiety, Dizziness, Asthenia, Product use issue, Product use in unapproved indication, |
||||
LIRAGLUTIDE, LIRAGLUTIDE, LIRAGLUTIDE, ORAL SEMAGLUTIDE, SIROLIMUS, PREDNISONE, INSULIN GLARGINE-YFGN, INSULIN GLARGINE, |
||||
| 14 | 26941437 |
US |
69 | |
Ileus, Intestinal obstruction, Emotional distress, Product use issue, |
||||
ORAL SEMAGLUTIDE, ORAL SEMAGLUTIDE, ORAL SEMAGLUTIDE, |
||||
| 15 | 26941459 |
US |
2 | |
Emergency care, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 16 | 26941593 |
US |
68 | 2 |
Product dose omission in error, Device issue, Drug dose omission by device, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 17 | 26941599 |
US |
2 | |
Adverse event, Heart rate increased, Liquid product physical issue, Product dose omission issue, Product use issue, Device failure, |
||||
ABALOPARATIDE, |
||||
| 18 | 26941749 |
US |
2 | |
Hospitalisation, Emergency care, Spinal pain, Musculoskeletal pain, Injection site pain, Product dose omission issue, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 19 | 26941889 |
US |
2 | |
Inadvertent injection air bubble, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 20 | 26941894 |
US |
2 | |
Contusion, Injection site pain, Product dose omission issue, Product use issue, |
||||
ABALOPARATIDE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, |
||||
| 21 | 26941923 |
US |
79 | 2 |
Joint swelling, Arthralgia, Product use in unapproved indication, Product use issue, |
||||
ABALOPARATIDE, ABALOPARATIDE, ETANERCEPT, SARILUMAB, MEPOLIZUMAB, |
||||
| 22 | 26941947 |
BR |
70 | 2 |
Asphyxia, Renal failure, Product use issue, Dengue fever, Osteoporosis, Device malfunction, Off label use, |
||||
BECLOMETHASONE DIPROPIONATE/FORMOTEROL FUMARATE/GLYCOPYRROLATE, BECLOMETHASONE DIPROPIONATE/FORMOTEROL FUMARATE/GLYCOPYRROLATE, BECLOMETHASONE DIPROPIONATE/FORMOTEROL FUMARATE/GLYCOPYRROLATE, BECLOMETHASONE DIPROPIONATE/FORMOTEROL FUMARATE/GLYCOPYRROLATE, CALCIUM, AMLODIPINE BESYLATE, |
||||
| 23 | 26942041 |
US |
67 | 2 |
Product dose omission issue, Product use issue, Product supply issue, |
||||
ABALOPARATIDE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, |
||||
| 24 | 26942273 |
EU |
39 | 1 |
Overdose, Product use issue, Drug dependence, Product use in unapproved indication, |
||||
ZOLPIDEM TARTRATE, OXAZEPAM, METHADONE, OXAZEPAM, |
||||
| 25 | 26942412 |
US |
38 | 2 |
Eye operation, Prescribed underdose, Product use issue, |
||||
PERFLUOROHEXYLOCTANE, SERTRALINE, PHENTERMINE AND TOPIRAMATE, |
||||
| 26 | 26942461 |
US |
||
Hospitalisation, Product use issue, |
||||
BOSENTAN, |
||||
| 27 | 26942508 |
EU |
12 | 2 |
Respiratory failure, Hypertriglyceridaemia, Gastrointestinal haemorrhage, Renal failure, Respiratory syncytial virus infection, Hypoalbuminaemia, Pancytopenia, Hepatotoxicity, Circulatory collapse, Electrolyte imbalance, Polyneuropathy, Coagulopathy, Clostridium difficile infection, Therapy non-responder, Cachexia, Infection, Product use in unapproved indication, Product use issue, |
||||
FILGRASTIM, IMATINIB MESYLATE, IMATINIB, IMATINIB MESYLATE, IMATINIB, DAUNORUBICIN HYDROCHLORIDE, BUDESONIDE, BUDESONIDE, CALASPARGASE PEGOL, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYTARABINE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DOXORUBICIN, ETOPOSIDE, HUMAN IMMUNOGLOBULIN G, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, IFOSFAMIDE, IFOSFAMIDE FOR INJECTION, IMATINIB MESYLATE, IMATINIB, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, METHOTREXATE SODIUM, METHYLPREDNISOLONE, PEGASPARGASE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, VINCRISTINE SULFATE, CLARITHROMYCIN, MEROPENEM, VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN, |
||||
| 28 | 26942583 |
57 | ||
Injection site granuloma, Product use issue, |
||||
DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, |
||||
| 29 | 26942653 |
US |
74 | 2 |
Product use issue, Incorrect dose administered, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 30 | 26942712 |
US |
||
Product dose omission issue, Product use issue, No adverse event, |
||||
SITAGLIPTIN PHOSPHATE, |
||||
| 31 | 26942901 |
US |
||
Product use issue, No adverse event, |
||||
AMLODIPINE BESYLATE, |
||||
| 32 | 26943027 |
US |
2 | |
Cardiac disorder, Product dose omission issue, Drug delivery system issue, Product use issue, |
||||
BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, |
||||
| 33 | 26943112 |
CA |
44 | 2 |
Breast cancer stage III, Folliculitis, Sciatica, Hypoaesthesia, Memory impairment, Dyspepsia, Taste disorder, Crohn^s disease, Bone erosion, Gait inability, Gastrooesophageal reflux disease, Pneumonia, Decreased appetite, Insomnia, Disability, Confusional state, Grip strength decreased, Sleep disorder due to a general medical condition, Product use in unapproved indication, Blister, Adjustment disorder with depressed mood, Dislocation of vertebra, Hypercholesterolaemia, Lip dry, Blepharospasm, Systemic lupus erythematosus, Therapeutic product effect decreased, Anxiety, Delirium, Impaired healing, Infusion site reaction, Malaise, Bursitis, Facet joint syndrome, Lower respiratory tract infection, Dyspnoea, Drug intolerance, Prescribed overdose, Helicobacter infection, Dizziness, Sleep disorder, Rash, Glossodynia, C-reactive protein increased, Ulcer haemorrhage, Incorrect route of product administration, Therapeutic product effect incomplete, Maternal exposure during pregnancy, Amnesia, Anti-cyclic citrullinated peptide antibody positive, Respiratory disorder, Psoriatic arthropathy, Urticaria, Depression, Contusion, Hepatic cirrhosis, Product quality issue, Hypersensitivity, Blood cholesterol increased, Drug hypersensitivity, Sinusitis, Exostosis, Discomfort, Deep vein thrombosis postoperative, Intentional product use issue, Condition aggravated, Diarrhoea, Hand deformity, Gait disturbance, Lower limb fracture, X-ray abnormal, Pericarditis, Stomatitis, Back injury, Duodenal ulcer perforation, Lupus-like syndrome, Ear pain, Ill-defined disorder, Alopecia, Fatigue, Synovitis, Type 2 diabetes mellitus, Prescribed underdose, Exposure during pregnancy, Rheumatoid factor positive, Product use issue, Epilepsy, Rheumatoid arthritis, Gastrointestinal disorder, Swollen joint count increased, Red blood cell sedimentation rate increased, Treatment failure, Irritable bowel syndrome, Contraindicated product administered, Swelling, Hypertension, Breast cancer stage II, Laryngitis, Drug ineffective, Pyrexia, Asthenia, Headache, Medication error, General physical health deterioration, Asthma, Therapy non-responder, Hepatic enzyme increased, Chest pain, Rheumatic fever, Drug tolerance, Fibromyalgia, Dry mouth, Peripheral swelling, Infusion related reaction, |
||||
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, INFLIXIMAB, ABATACEPT, OXYCODONE, OXYCODONE, CELECOXIB, CELECOXIB, MIRABEGRON, NAPROXEN, NAPROXEN SODIUM, PREDNISONE, PREDNISONE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE, SARILUMAB, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, SECUKINUMAB, MEPOLIZUMAB, MAGNESIUM CITRATE, MAJOR MAGNESIUM CITRATE ORAL SOLUTION - LEMON, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, CVS MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, EQUATE MAGNESIUM CITRATE ORAL SOLUTION - LEMON, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, MAGNESIUM CITRATE ORAL SOLUTION, EPIC MEDICAL MAGNESIUM CITRATE ORAL SOLUTION - LEMON, CVS MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, CVS MAGNESIUM CITRATE ORAL SOLUTION - LEMON, EQUATE MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - LEMON, LEADER MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, LEADER MAGNESIUM CITRATE ORAL SOLUTION - LEMON, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - LEMON, EQUATE MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, LEADER MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, HARRIS TEETER MAGNESIUM CITRATE ORAL SOLUTION - LEMON, MAGNESIUM CITRATE, MAJOR MAGNESIUM CITRATE ORAL SOLUTION - LEMON, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, CVS MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, EQUATE MAGNESIUM CITRATE ORAL SOLUTION - LEMON, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, MAGNESIUM CITRATE ORAL SOLUTION, EPIC MEDICAL MAGNESIUM CITRATE ORAL SOLUTION - LEMON, CVS MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, CVS MAGNESIUM CITRATE ORAL SOLUTION - LEMON, EQUATE MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - LEMON, LEADER MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, LEADER MAGNESIUM CITRATE ORAL SOLUTION - LEMON, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - LEMON, EQUATE MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, LEADER MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, HARRIS TEETER MAGNESIUM CITRATE ORAL SOLUTION - LEMON, MAGNESIUM CITRATE, MAJOR MAGNESIUM CITRATE ORAL SOLUTION - LEMON, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, CVS MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, EQUATE MAGNESIUM CITRATE ORAL SOLUTION - LEMON, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, MAGNESIUM CITRATE ORAL SOLUTION, EPIC MEDICAL MAGNESIUM CITRATE ORAL SOLUTION - LEMON, CVS MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, CVS MAGNESIUM CITRATE ORAL SOLUTION - LEMON, EQUATE MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - LEMON, LEADER MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, LEADER MAGNESIUM CITRATE ORAL SOLUTION - LEMON, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - LEMON, EQUATE MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, LEADER MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, HARRIS TEETER MAGNESIUM CITRATE ORAL SOLUTION - LEMON, CELECOXIB, CELECOXIB, RAMIPRIL, RAMIPRIL, LAMOTRIGINE, LAMOTRIGINE, NAPROXEN SODIUM, NAPROXEN SODIUM 220MG, NAPROXEN SODIUM, COATED TABLETS, NAPROXEN SODIUM TABLET, COATED, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, PREDNISONE, PREDNISONE, |
||||
| 34 | 26943399 |
EU |
73 | |
Lymphadenectomy, Gastrectomy, Gastric bypass, Product use issue, |
||||
TRASTUZUMAB, TRASTUZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, CISPLATIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 35 | 26943460 |
US |
59 | 2 |
Suicidal ideation, Depressed mood, Product distribution issue, Product use issue, |
||||
ANAKINRA, |
||||
| 36 | 26943574 |
EU |
72 | 2 |
Hallucination, visual, Hyperkinesia, Confusional state, Hallucination, Infusion site induration, Aggression, Product use issue, |
||||
FOSCARBIDOPA/FOSLEVODOPA, FOSCARBIDOPA/FOSLEVODOPA, FOSCARBIDOPA/FOSLEVODOPA, MELATONIN, GABAPENTIN, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, TORSEMIDE, CANDESARTAN, AMLODIPINE BESYLATE, BISOPROLOL FUMARATE, LATANOPROST, |
||||
| 37 | 26943577 |
US |
79 | |
Drug dose omission by device, Wrong technique in product usage process performed in error, Product use issue, No adverse event, |
||||
ALBUTEROL SULFATE, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, AMLODIPINE, LISINOPRIL, |
||||
| 38 | 26943853 |
US |
2 | |
Weight loss poor, Drug ineffective, Product use issue, Hunger, Food craving, |
||||
| 39 | 26943993 |
US |
1 | |
Product use issue, Off label use, |
||||
CABOTEGRAVIR AND RILPIVIRINE, CABOTEGRAVIR AND RILPIVIRINE, CABOTEGRAVIR AND RILPIVIRINE, LENACAPAVIR SODIUM, |
||||
| 40 | 26943997 |
CN |
75 | 1 |
Creatine kinase increased, Product use issue, |
||||
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, |
||||
| 41 | 26944032 |
US |
76 | 2 |
Accidental exposure to product, Product use issue, Mouth swelling, Swelling of nose, Oral pain, Eye irritation, |
||||
TIRBANIBULIN, AMLODIPINE, CARVEDILOL, |
||||
| 42 | 26944319 |
VN |
5 | |
Drug ineffective, Product use in unapproved indication, Product use issue, |
||||
TENOFOVIR DISOPROXIL FUMARATE, |
||||
| 43 | 26944334 |
CA |
44 | 2 |
Condition aggravated, Drug intolerance, Pregnancy, Treatment failure, Drug ineffective, Contraindicated product administered, Product use issue, Therapeutic product effect decreased, Medication error, Injury, Maternal exposure during pregnancy, |
||||
DICLOFENAC SODIUM, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, OXYCODONE HYDROCHLORIDE, OXYCODONE, OXYCODONE HYDROCHLORIDE, OXYCODONE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, LEFLUNOMIDE, LEFLUNOMIDE, OXYCODONE, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, RITUXIMAB, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, ALENDRONATE SODIUM, |
||||
| 44 | 26944394 |
US |
67 | 2 |
Product dose omission issue, Myalgia, Product use issue, |
||||
TIRZEPATIDE, TIRZEPATIDE, |
||||
| 45 | 26944422 |
US |
42 | 2 |
Seizure, Therapy interrupted, Fall, Product use issue, Overdose, Insurance issue, |
||||
BRIVARACETAM, BRIVARACETAM, BRIVARACETAM, |
||||
| 46 | 26944431 |
US |
62 | 2 |
Product use issue, |
||||
ABATACEPT, |
||||
| 47 | 26944782 |
US |
64 | 2 |
Somnolence, Hot flush, Bone pain, Fatigue, Dizziness, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 48 | 26944865 |
US |
2 | |
Blister, Fluid retention, Pollakiuria, Breast enlargement, Somnolence, Weight increased, Nausea, Headache, Vertigo, Dizziness, Fatigue, Bone pain, Arthralgia, Injection site reaction, Product use issue, Product administered at inappropriate site, Product dose omission issue, |
||||
ABALOPARATIDE, ABALOPARATIDE, ABALOPARATIDE, ABALOPARATIDE, ABALOPARATIDE, |
||||
| 49 | 26944964 |
US |
2 | |
Feeling abnormal, Headache, Heart rate increased, Nausea, Dizziness, Tachycardia, Product use issue, |
||||
ABALOPARATIDE, ABALOPARATIDE, |
||||
| 50 | 26945053 |
US |
2 | |
Nasopharyngitis, Ill-defined disorder, Fatigue, Pain, Product dose omission issue, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 51 | 26945109 |
US |
83 | 2 |
Product container seal issue, Incorrect dose administered by device, Product use issue, Wrong technique in product usage process, Product communication issue, Device issue, |
||||
ABALOPARATIDE, ABALOPARATIDE, |
||||
| 52 | 26945298 |
US |
2 | |
Haemorrhoids, Fatigue, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 53 | 26945390 |
EU |
73 | 1 |
Epilepsy, Product use issue, Product dose omission in error, Balance disorder, Myalgia, |
||||
LACOSAMIDE, |
||||
| 54 | 26945398 |
US |
72 | |
Flatulence, Diarrhoea, Product use issue, |
||||
ABALOPARATIDE, ABALOPARATIDE, |
||||
| 55 | 26945487 |
2 | ||
Product use issue, |
||||
RISANKIZUMAB-RZAA, |
||||
| 56 | 26945494 |
US |
2 | |
Emergency care, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 57 | 26945785 |
US |
2 | |
Emergency care, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 58 | 26945849 |
US |
2 | |
Spinal pain, Myalgia, Blood phosphorus increased, Iodine uptake increased, Headache, Back pain, Dizziness, Blood calcium increased, Product use issue, |
||||
ABALOPARATIDE, ABALOPARATIDE, |
||||
| 59 | 26946001 |
US |
2 | |
Depression, Headache, Nausea, Fatigue, Product use issue, |
||||
ABALOPARATIDE, ABALOPARATIDE, ABALOPARATIDE, |
||||
| 60 | 26946037 |
US |
2 | |
Adverse drug reaction, Urinary tract infection, Abdominal pain upper, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 61 | 26946105 |
US |
2 | |
Illness, Product use issue, |
||||
ABALOPARATIDE, ABALOPARATIDE, |
||||
| 62 | 26946112 |
US |
55 | 2 |
Injection site urticaria, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 63 | 26946116 |
US |
73 | 2 |
Feeling abnormal, Headache, Product use issue, Drug titration, |
||||
ABALOPARATIDE, ABALOPARATIDE, BUPRENORPHINE HYDROCHLORIDE, BUPROPION, CYCLOBENZAPRINE, DONEPEZIL HYDROCHLORIDE, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, MINOXIDIL, MINOXIDIL FOAM 5% (WOMENS), OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, SIMVASTATIN, |
||||
| 64 | 26946119 |
US |
2 | |
Product use issue, Diarrhoea, Vomiting, |
||||
| 65 | 26946123 |
US |
17 | |
Hospitalisation, Product use issue, Product use issue, |
||||
CENOBAMATE, CENOBAMATE, |
||||
| 66 | 26946153 |
US |
67 | 2 |
Inappropriate schedule of product administration, Product dose omission issue, Product use issue, Product complaint, |
||||
FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 67 | 26946194 |
US |
83 | 2 |
Device delivery system issue, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 68 | 26946247 |
US |
57 | 1 |
Hepatic failure, Renal failure, Diabetes mellitus, Product use issue, Product prescribing issue, Product use in unapproved indication, |
||||
RIFAXIMIN, RIFAXIMIN, |
||||
| 69 | 26946400 |
US |
77 | 2 |
Hospitalisation, Gait disturbance, Therapy interrupted, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 70 | 26946488 |
US |
2 | |
Eye operation, Visual acuity reduced, Myopia, Adverse event, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 71 | 26946509 |
US |
81 | 2 |
Hypoaesthesia, Peripheral swelling, Joint swelling, Memory impairment, Muscle spasms, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 72 | 26946603 |
US |
72 | 1 |
Injection site discomfort, Bone pain, Arthralgia, Product dose omission issue, Product use issue, |
||||
ABALOPARATIDE, ABALOPARATIDE, ABALOPARATIDE, CLOPIDOGREL, CLOPIDOGREL BISULFATE, |
||||
| 73 | 26946681 |
US |
84 | 2 |
Hospitalisation, Influenza, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 74 | 26946722 |
US |
2 | |
Memory impairment, Disturbance in attention, Headache, Product use issue, |
||||
ABALOPARATIDE, TIZANIDINE, GABAPENTIN, |
||||
| 75 | 26946771 |
US |
2 | |
Device defective, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 76 | 26946919 |
US |
73 | 2 |
Product dose omission in error, Product use issue, |
||||
ABALOPARATIDE, ABALOPARATIDE, ALBUTEROL SULFATE, CITALOPRAM, CITALOPRAM HYDROBROMIDE, FAMOTIDINE, GABAPENTIN, LISINOPRIL, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, NAPROXEN SODIUM, DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, GUAIFENESIN, NAPROXEN SODIUM, PSEUDOEPHEDRINE HYDROCHLORIDE, |
||||
| 77 | 26946926 |
US |
1 | |
Spinal pain, Erythema, Headache, Pain, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 78 | 26946947 |
US |
2 | |
Illness, Hypersomnia, Cough, Chest discomfort, Oropharyngeal pain, Rhinorrhoea, Product dose omission issue, Product use issue, |
||||
ABALOPARATIDE, CALCIUM, ERGOCALCIFEROL, |
||||
| 79 | 26946959 |
US |
2 | |
Amenorrhoea, Intermenstrual bleeding, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 80 | 26947115 |
CN |
63 | 1 |
Myelosuppression, Vomiting, Rash, Diarrhoea, Abdominal discomfort, Urticaria, Hypersensitivity, Product use issue, |
||||
IVOSIDENIB, AZACITIDINE, AZACITIDINE FOR, VENETOCLAX, CYTARABINE, WATER, STERILE WATER, STERILE WATER FOR INJECTION, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, |
||||
| 81 | 26947116 |
CN |
2 | |
Myelosuppression, Platelet count decreased, Product use issue, |
||||
IVOSIDENIB, VENETOCLAX, AZACITIDINE, AZACITIDINE FOR, |
||||
| 82 | 26947171 |
US |
54 | 2 |
Drug dose omission by device, Product dose omission issue, Product use issue, Device mechanical issue, |
||||
ABALOPARATIDE, |
||||
| 83 | 26947213 |
US |
30 | 1 |
Injection site discomfort, Product use issue, |
||||
ABALOPARATIDE, CALCIUM, METHOCARBAMOL, METHOCARBAMOL TABLETS, ACETAMINOPHEN, NAPROXEN SODIUM, NAPROXEN SODIUM TABLET, LACOSAMIDE, LEVETIRACETAM, |
||||
| 84 | 26947214 |
US |
2 | |
Muscle spasms, Palpitations, Tooth deposit, Product use issue, |
||||
ABALOPARATIDE, MAGNESIUM, ERGOCALCIFEROL, QUERCETIN, QUERCETIN,, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, LEVOTHYROXINE SODIUM, |
||||
| 85 | 26947244 |
US |
2 | |
Myalgia, Irritability, Immune system disorder, Influenza like illness, Feeling abnormal, Palpitations, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 86 | 26947298 |
US |
2 | |
Injection site vesicles, Injection site pain, Dizziness, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 87 | 26947315 |
US |
23 | 1 |
Gastrointestinal disorder, Condition aggravated, Abdominal pain, Product use issue, |
||||
ABALOPARATIDE, ADALIMUMAB-ADAZ, |
||||
| 88 | 26947317 |
US |
2 | |
Muscle spasms, Back pain, Injection site swelling, Alopecia, Product use issue, Incorrect route of product administration, |
||||
ABALOPARATIDE, |
||||
| 89 | 26947412 |
US |
29 | 1 |
Product dose omission in error, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 90 | 26947532 |
US |
36 | 2 |
Skin irritation, Injection site pain, Device mechanical issue, Product use issue, Drug dose omission by device, Incorrect dose administered by device, Product use issue, |
||||
ABALOPARATIDE, ABALOPARATIDE, |
||||
| 91 | 26947822 |
US |
59 | 2 |
Skin irritation, Herpes zoster, Device malfunction, Product use issue, Drug dose omission by device, Product administered at inappropriate site, |
||||
ABALOPARATIDE, ABALOPARATIDE, |
||||
| 92 | 26947904 |
US |
61 | 2 |
Fall, Limb injury, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 93 | 26947986 |
US |
2 | |
Burning sensation, Pollakiuria, Chest pain, Throat irritation, Dysuria, Dyspepsia, Bone disorder, Feeling abnormal, Malaise, Dizziness, Heart rate increased, Headache, Product use in unapproved indication, Product use issue, |
||||
ABALOPARATIDE, ABALOPARATIDE, ABALOPARATIDE, |
||||
| 94 | 26948013 |
US |
2 | |
Dyspepsia, Pain in extremity, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 95 | 26948043 |
US |
2 | |
Bone density decreased, Musculoskeletal discomfort, Heart rate abnormal, Migraine, Heart rate increased, Dizziness, Fatigue, Palpitations, Drug effect less than expected, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 96 | 26948054 |
US |
75 | 2 |
Adverse event, Tongue coated, Swollen tongue, Blood calcium increased, Intentional product misuse, Product use issue, |
||||
ABALOPARATIDE, ABALOPARATIDE, ABALOPARATIDE, ABALOPARATIDE, |
||||
| 97 | 26948071 |
US |
1 | |
Irritable bowel syndrome, Dry eye, Eye pruritus, Product use issue, |
||||
ICOTROKINRA, |
||||
| 98 | 26948088 |
US |
35 | 2 |
Hospitalisation, Emergency care, Product use issue, |
||||
ABALOPARATIDE, TEZEPELUMAB-EKKO, |
||||
| 99 | 26948167 |
US |
1 | |
Chest pain, Heart rate increased, Palpitations, Product use issue, |
||||
ABALOPARATIDE, |
||||
| 100 | 26952200 |
65 | 2 | |
Therapy interrupted, Asthma, Infection, Product use issue, |
||||
TEZEPELUMAB-EKKO, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30